2017 ARVO Annual Meeting, Baltimore, Maryland (US)
The company will present several posters on both its lead products and an oral presentation on its GS030 optogenetics product.
– GS010 aiming at treating LHON, a rare mitochondrial genetic disease
Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON.
Poster session: Wednesday 10 May, 2017, 11.00am – 12.45pm, Session Low Vision Populations, Services and Treatments, Posterboard #: B0588, Abstract Number: 4681 – B0588
Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials.
Poster session: Wednesday 10 May, 2017, 8.30am – 10.15am, Session Optic Neuropathy, Posterboard #: A0036, Abstract Number: 3865 – A0036
– GS030 based on optogenetics to treat RP
Long term visual restoration using optogenetic engineering of retinal ganglion cells with AAV2.7m8- ChrimsonR-tdTomato
Oral presentation: Tuesday 9 May, 9.15-9.30 am, Session Diseases and Protection, Abstract Number # 1219
Visual acuity and optical flow in primate retinal ganglion cells treated with an optogenetic vision restoration strategy using ChrimsonR
Poster session: Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0475 – Abstract Number: 5883 – B0475
Modeling the dynamics of light-driven microbial opsin ChrimsonR
Poster session: Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0465 – Abstract Number: 5873 – B0465